ArticleNeuroradiology2025
Potential role of MELD and MAP18 in patients with structural temporal lobe epilepsy.
Article in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study compared two image post-processing toolboxes primarily designed for focal cortical dysplasia (FCD): Multi-Centre Epilepsy Lesion Detection (MELD) and Morphometric Analysis Program (MAP18), in identifying temporal lobe epilepsy (TLE) structural lesions on MRI.
methodsThis retrospective study examined 79 adults, 58 patients with confirmed TLE, and 21 healthy controls. All participants underwent an elective brain MRI between June 2007 - May 2023 at Hospital Clinic, Barcelona, Spain. All the 3D T1-weighted images were processed using MELD and MAP18 to detect potential epileptogenic lesions. The location (lateral or mesial) and laterality of the reference TLE structural lesion (refTLE) were determined through histopathology or multidisciplinary consensus based on clinical data. Toolboxes' performance was evaluated using descriptive statistics, specificity, and diagnostic accuracy. Additionally, a second-look MRI was conducted for cases where abnormalities detected by MELD and MAP18 did not match the refTLE.
resultsMELD and MAP18 demonstrated variability in specificity and diagnostic accuracy. Specificity ranged from 48% to 86%, with ProbMAP (MAP18) achieving the highest values. Global diagnostic accuracy ranged from 7% to 42%, with MELD showing the highest performance. In four patients with visible epileptogenic lesions on MRI, MELD and MAP18 identified additional abnormalities that were previously overlooked. Moreover, MELD detected one TLE lesion in one patient initially classified as MRI-negative (nonlesional).
conclusionIncorporating tools like MELD and MAP18 into the diagnostic workflow can enhance the detection of TLE-related abnormalities on MRI, potentially improving patient outcomes and aiding in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.